Envíos recientes

eIF4A dependency: the hidden key to unlock KRAS mutant non-small cell lung cancer’s vulnerability

Casacuberta-Serra, Sílvia; González-Larreategui, Íñigo; Soucek, Laura (Fecha de publicación: 2024-01-17)

MYC; Non-small cell lung cancer

The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability

ABAD, ETNA; Sandoz, Jeremy; Romero Sola, Gerard; Zadra, Ivan; Urgel-Solas, Julia; Borredat, Pablo (Fecha de publicación: 2024-05-22)

Aneuploidy; Cancer; Genomic instability

Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study

Garcia-Casado, Zaida; Oaknin Benzaquen, Ana Mazaltob; Mendiola, Marta; Alkorta-Aranburu, Gorka; Antunez-Lopez, Jose Ramon; Moreno-Bueno, Gema (Fecha de publicación: 2022-12-02)

Ovarian cancer; BRCA mutations; BRCA testing

MYC inhibitors in multiple myeloma

Martínez Martín, Sandra; Soucek, Laura (Fecha de publicación: 2022-06-28)

MYC inhibition; Targeted therapies; Epigenetics

Editorial: MYC as a disease target beyond cancer

Whitfield, Jonathan (Fecha de publicación: 2024-10-15)

Enfermedades no oncológicas; Focalización; Factor de transcripción

Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab

Yang, S. Y. Cindy; Han, Ming; Liu, Zhihui Amy; Berman, A Hal K.; Lo Giacco, Deborah; Berche, Roger; Hernando-Calvo, Alberto; Vila-Casadesús, Maria; Matito, Judit; Saavedra, Omar; GARRALDA, Elena; Vivancos, Ana (Fecha de publicación: 2025-02-14)

Biomarker; Circulating tumor DNA; Advanced solid tumors

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors

Ong, Michael; Rodriguez-Ruiz, Maria E; Machiels, Jean-Pascal; Sanmamed, Miguel F.; Gambardella, Valentina; Galvao, Vladimir (Fecha de publicación: 2025-04-10)

Antitumor Activity; Solid tumors

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

Braña Garcia, Irene; Longhi, Alessandra; Awada, Ahmad; Subbiah, Vivek; Boni, Valentina; Delord, Jean-Pierre (Fecha de publicación: 2022-09-09)

Ewing Sarcoma; Lurbinectedin

Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation

Xu, Yan; Zhao, Yanqiu; Doucet, Ludovic; Zhou, Jianying; Wang, Yongsheng; Yang, James Chih-Hsin; FELIP, ENRIQUETA (Fecha de publicación: 2025-06-10)

Non-small cell lung cancer; Biomarker; Sunvozertinib

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop

de Jager, Vincent D.; Giacomini, Patrizio; Fairley, Jennifer A.; Patton, Simon; Joosse, Simon A.; Toledo, Rodrigo (Fecha de publicación: 2025-04-29)

Consensus; Liquid biopsy; ctDNA test

Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design

Miguel-Huguet, Bernat; Perez-Garcia, Jose Manuel; Páez, David; Guerrero‑Zotano, Angel; Cortés Castan, Javier; Sampayo-Cordero, Miguel; Garde-Noguera, Javier (Fecha de publicación: 2021-10-29)

No inferioridad; Fase II; Brazo único

First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

MARTINEZ JAÑEZ, NOELIA; Luis, Manso; Henao, Fernando; Antón Torres, Antonio; Bellet Ezquerra, Meritxell; Morales, Serafin (Fecha de publicación: 2024-06-19)

Advanced breast cancer; First-line treatment; Progression-free survival

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice

DEANDREIS, Desiree'; DURANTE, COSIMO; Luster, Markus; Netea-Maier, Romana; Capdevila Castillon, Jaume; Leboulleux, Sophie (Fecha de publicación: 2023-08-22)

Differentiated thyroid cancer; Lenvatinib; Toxicity

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

Lopez-Bonet, Eugeni; Buxó, Maria; Cuyàs, Elisabet; Pernas, Sonia; Dorca, Joan; Álvarez, Isabel; Cortés Castan, Javier (Fecha de publicación: 2021-04-13)

Metformina; Ki67; Càncer de mama

Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Cortés Castan, Javier; Miceli, Rosalba; Di Cosimo, Serena; Malfettone, Andrea; Porcu, Luca (Fecha de publicación: 2021-09-10)

COVID-19; Atenció al càncer; Orientació del pacient

Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study

Santos Vivas, Cristina; La Casta, Adelaida; García-Alfonso, Pilar; Jimenez Fonseca, Paula; Soto Alsar, Javier; Baraibar, Iosune (Fecha de publicación: 2025-09-16)

Coronavirus disease; Gastrointestinal cancer; Spatial frailties

Considerations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 1: In vivo small-animal imaging

Jelescu, Ileana; Hansen, Brian; Barrett, Rachel L. C.; Aggarwal, Manisha; Grussu, Francesco; Ianus, Andrada (Fecha de publicación: 2025-04-22)

Diffusion MRI; Diffusion tensor; Small animal

Articles científics - VHIO: Envíos recientes

eIF4A dependency: the hidden key to unlock KRAS mutant non-small cell lung cancer’s vulnerability

The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability

Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study

MYC inhibitors in multiple myeloma

Editorial: MYC as a disease target beyond cancer

Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop

Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design

First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study

Considerations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 1: In vivo small-animal imaging

Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc

Articles científics - VHIO: Envíos recientes

eIF4A dependency: the hidden key to unlock KRAS mutant non-small cell lung cancer’s vulnerability ﻿

The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability ﻿

Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study ﻿

MYC inhibitors in multiple myeloma ﻿

Editorial: MYC as a disease target beyond cancer ﻿

Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab ﻿

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors ﻿

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study ﻿

Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation ﻿

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop ﻿

Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design ﻿

First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN ﻿

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice ﻿

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer ﻿

Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China ﻿

Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study ﻿

Considerations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 1: In vivo small-animal imaging ﻿

Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer ﻿

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy ﻿

Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc ﻿

eIF4A dependency: the hidden key to unlock KRAS mutant non-small cell lung cancer’s vulnerability

The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability

Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study

MYC inhibitors in multiple myeloma

Editorial: MYC as a disease target beyond cancer

Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop

Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design

First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study

Considerations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 1: In vivo small-animal imaging

Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc